Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03181477
Other study ID # 2016-A000679-42
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 7, 2017
Est. completion date September 2, 2025

Study information

Verified date October 2023
Source Centre Georges Francois Leclerc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Glioblastoma (GBM) is the most aggressive and most frequent brain tumour. Approximately four people per 100,000 inhabitants are diagnosed with this disease every year. The standard treatment comprises surgical resection (whenever possible), normofractionated radiotherapy at a dose of 60Gray (Gy) and temozolomide (TMZ). Median overall survival in these patients is 14.6 months [13.2-16.8]. In a previous phase I clinical trial, dose escalation tolerance using simultaneous-integrated boost intensity-modulated radiation therapy (SIB-IMRT) technic has been evaluated. The investigator demonstrated that SIB-IMRT until a dose of 80Gy in 32 daily fractions, associated with TMZ is feasible and well tolerated by patients with glioblastoma. The aim of this present phase II clinical trial is to evaluate the overall survival at 18 months for patients with glioblastoma receiving TMZ, according to standard protocol, associated to radiotherapy delivered at 80Gy using SIB-IMRT technic. The first planning target volume (PTV), including oedema and tumour highlighted on T2 flair magnetic resonance imaging (MRI) sequences, will receive 60.8Gy in 32 daily fractions. The second PTV, including tumour highlighted on T1 MRI sequences, will receive 80.0Gy in 32 daily fractions. Secondary objectives are tolerance, survival free progression and quality of live evaluations. Sixty seven patients will be enrolled in this present trial.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 67
Est. completion date September 2, 2025
Est. primary completion date September 2, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients aged from 18 to 70 years old. - Patients with a unifocal Glioblastoma (grade IV astrocytoma in the World Health Organization (WHO) classification) with postoperative macroscopic residue after biopsy or resection alone. - Location of the tumor or residual tumor, detected by Magnetic Resonance Imaging (MRI) sequences T1 gadolinium, more than 1cm from the optic chiasm - Diagnosis confirmed by pathology. - Time from surgery (if performed) and the start of radiation therapy less than 6 weeks. - performance status 0 or 1 in the WHO classification. - methylation status of the MGMT promoter gene requested - blood count: Neutrophil more than 1500/mm3 Platelets more than 100 000/mm3 - Liver function test Bilirubin less than 1,5 times upper limit transaminases than 3 times upper limit - patient informed and informed consent signed - Possibility to trat by radiation withintensity modulated (fixed beams modulated or rotational modulation (TomoTherapy, dynamic arctherapy)) strictly respecting the constraints to organs at risk (Crystalline: 8 Gy max, Posterior chamber of the eye: 45 Gy max , optic nerve: 54 Gy max, chiasm: 54 Gy max, brain Stem: 2% 58 Gy D2 <64 Gy, Dmax <69 Gy spinal cord: 46 Gy max, healthy brain (brain - PTV): 60 Gy max 33%, 50 Gy to 50% and D100 <45 Gy to the brain in toto). - The patient must be affiliated to a social security scheme. Exclusion Criteria: - Other histological "Glioblastoma". - Excision macroscopically complete individualized on postoperative MRI. - Patient unable to give consent. - A patient with against-indication to performed MRI (pacemaker, uncontrollable claustrophobia ...). - The patient must not have received radiation therapy or previous chemotherapy for this condition. - Other neoplasia unstabilized and / or treated for less than 5 years. - Patient already included in another clinical trial with an experimental molecule. - Inability to submit to medical monitoring testing for geographical, social or psychological. - Pregnancy or breastfeeding - Private Person of liberty under supervision or under curatorship - No affiliation to a social security scheme or medical state aid or the universal medical coverage

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Radiotherapy
Radiotherapy of 80 GY + Chemotherapy (Temozolomide)

Locations

Country Name City State
France CHU Amiens Picardie Amiens
France CHU Besançon Besançon
France Centre Georges François Leclerc Dijon
France Centre d'oncologie et de radiothérapie Mâcon
France Institut de cancérologie de Lorraine Nancy
France Paul Strauss Strasbourg
France Centre de cancérologie des dentellières Valenciennes

Sponsors (1)

Lead Sponsor Collaborator
Centre Georges Francois Leclerc

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival 18 months
See also
  Status Clinical Trial Phase
Completed NCT03291977 - Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME) Phase 3
Active, not recruiting NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma Phase 1/Phase 2
Terminated NCT03714334 - DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma Phase 1
Recruiting NCT03277638 - Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM) Phase 1/Phase 2
Completed NCT03158389 - NCT Neuro Master Match - N²M² (NOA-20) Phase 1/Phase 2
Completed NCT03522298 - Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma Phase 2
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Completed NCT03232424 - NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma Phase 1
Active, not recruiting NCT04116658 - First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma Phase 1/Phase 2
Completed NCT03618667 - GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification Phase 2
Recruiting NCT04128774 - Function and Composition of Regulatory B Cells in Participants With Glioblastoma
Completed NCT03744026 - Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9 Phase 1/Phase 2
Completed NCT04610229 - Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. N/A
Active, not recruiting NCT02974738 - A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) Phase 1
Recruiting NCT03025893 - A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Phase 2/Phase 3
Completed NCT03075514 - Ketogenic Diets as an Adjuvant Therapy in Glioblastoma N/A